中国实用妇科与产科杂志

中国实用妇科与产科杂志 ›› 2022, Vol. 38 ›› Issue (7): 693-696.DOI: 10.19538/j.fk2022070107

• 专题笔谈 • 上一篇    下一篇

妊娠滋养细胞肿瘤的免疫治疗

  

  1. 中国医学科学院 北京协和医学院 北京协和医院妇产科，北京100730
  • 出版日期:2022-07-02 发布日期:2022-07-02
  • 通讯作者: 向阳
  • 基金资助:
    国家自然科学基金（81971475，81972451）

Immunotherapy for gestational trophoblastic neoplasia. 

  1. Department of Gynecology and Obstetrics，Peking Union Medical College Hospital，Peking Union Medical College，Chinese Academy of Medical Sciences，Beijing 100730，China
  • Online:2022-07-02 Published:2022-07-02

摘要： 妊娠滋养细胞肿瘤（gestational trophoblastic neoplasia，GTN）是由妊娠继发的疾病，虽然对化疗高度敏感，但仍有部分患者因耐药、复发而死亡。由于疾病起源与免疫密切相关，免疫治疗在难治性GTN中的尝试初显成效。随着对新兴免疫靶点研究的不断深入，免疫治疗逐渐成为近年来GTN挽救治疗的研究热点，文章将重点讨论GTN的免疫治疗研究进展。

关键词: 妊娠滋养细胞肿瘤, 免疫治疗, 程序性死亡蛋白1

Abstract: Gestational trophoblastic neoplasia （GTN） is a subsequent disease to pregnancy. Although it is highly sensitive to chemotherapy，some patients still died of drug resistance and relapse. Since the disease origin is closely related to immunity，immunotherapy has shown initial success in refractory GTN. With the deepening of the research on emerging immune targets，immunotherapy has gradually become the focus of GTN salvage therapy in recent years. This review will focus on the research progress about immunotherapy for GTN.

Key words: gestational trophoblastic neoplasia, immunotherapy, programmed death protein-1

中图分类号: